Klarman’s Kleryx holding transitions into stake in fully integrated kidney care company with investor’s approval
Category: NYSE:AGN
Tax Reform No Shot In Arm For Pharma Deals
Divests are plentiful but mega-deals lag.
Did Pfizer Blink And What Will Pharma Do Now?
Pfizer confirmed that time has run out for raising prices without blow-back. The renewed attention to drug price hikes means business as usual has ended and two questions loom large for Pharma. Is talk of regulation of drug prices next and who will ne…
